Tests carrot juice in adults after bowel polyp removal
Compares carrot juice rich in polyacetylenes with placebo juice in adults after polyp removal.
Plain-language title generated from the registry record
Registry title: Prophylactic Properties of Carrot Juice in Patients With High-Risk Colorectal Polyps
Key facts
- Where
- Odense, DenmarkSee the site
Where in Denmark
- Department of Surgery, Odense University HospitalOdense, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Odense University Hospital
- Trial code
- NCT06335420
- Record updated
- 20 November 2025
- Original description
The goal of this prospective randomized double-blinded bi-national study is to test the prophylactic effect of polyacetylenes from carrots on the population of patients who had a resection of high-risk adenomas of the large bowel.Read full original descriptionShow less
Polyp Prophylactic Properties of Polyacetylenes in Patients With Previous Polypectomy
The goal of this prospective randomized double-blinded bi-national study is to test the prophylactic effect of polyacetylenes from carrots on the population of patients who had a resection of high-risk adenomas of the large bowel.
The main question it aims to answer is: Will carrot juice rich in polyacetylenes inhibit neoplastic transformation and growth in high-risk humans?
Participants will have to drink 100 ml of juice daily after the adenoma resection for 1 year and keep a simple diary/calendar.
Researchers will compare the group with ingestion of Falcarinol (FaOH) / Falcarindiol (FaDOH) rich carrot juice versus the group consuming placebo juice, to see if the polyacetylenes significantly reduces neoplastic transformation and growth in high-risk patients.
Inclusion: Any type of resection for adenomas larger than 20 mm in size (endoscopically evaluated) or endoscopically resected T1 cancers; Acceptance of the treatment and follow-up program; Capability to understand and follow the instructions.
Exclusion: Chronic consumption of COX (cyclooxygenase) inhibitors (Aspirin, Celecoxib, Ibuprofen, Diclofenac, Ketoprofen, Ketorolac, Indometacin, Naproxen, Piroxicam) or immunosuppressive agents (Methotrexate, Azathioprine or glucocorticoids); Known relevant allergies; Patients with different neoplastic disease under treatment (Chemo-/Radio-/Imunotherapy); Lynch syndrome; Patients allocated to "high-risk" group because of many small polyps (>4); Pregnancy; Severe comorbidity NYHA III-IV.